Berenberg Bank reiterated their buy rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note published on Sunday morning. The firm currently has a $86.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $79.00.

A number of other research analysts have also weighed in on GILD. BidaskClub lowered shares of Gilead Sciences from a buy rating to a hold rating in a research note on Wednesday, August 9th. Deutsche Bank AG reaffirmed a buy rating and issued a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann reaffirmed a hold rating and issued a $74.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. Cowen and Company reaffirmed an outperform rating and issued a $90.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a hold rating and issued a $83.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Eleven equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has an average rating of Buy and an average target price of $80.64.

Gilead Sciences (GILD) opened at 73.34 on Friday. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $82.10. The firm has a market cap of $95.78 billion, a price-to-earnings ratio of 7.97 and a beta of 1.21. The firm has a 50-day moving average of $72.66 and a 200 day moving average of $68.77.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the previous year, the firm posted $3.08 earnings per share. The business’s revenue was down 8.2% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.74 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Berenberg Bank Reaffirms Buy Rating for Gilead Sciences, Inc. (GILD)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/23/berenberg-bank-reaffirms-buy-rating-for-gilead-sciences-inc-gild.html.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences’s payout ratio is presently 22.58%.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. In the last three months, insiders sold 206,666 shares of company stock valued at $15,223,184. 1.30% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in GILD. Hall Laurie J Trustee boosted its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC boosted its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. boosted its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. 74.02% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.